FILING ANALYSIS · THURSDAY, NOVEMBER 12
Pelthos Therapeutics Inc. PTHS — 8-K: Results of Operations and Financial Condition
positive
Pelthos Therapeutics reported a 114% year-over-year increase in Zelsuvmi net product revenue to $15.2 million, driven by strong utilization and increased formulary coverage, and announced a transformative merger with Castle Creek to create a diversified biotechnology company with significant upside potential.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →